< back to headlines

October 6, 2006

Aegerion Pharmaceuticals Enters into Cross License Agreement

Agreement expands Aegerion platform for development and global commercialization of new therapies for cholesterol management

BRIDGEWATER, NJ (October 6, 2006) Aegerion Pharmaceuticals, Inc., in collaboration with Pfizer Inc and the University of Pennsylvania, have entered into a cross-license relationship covering a range of patents related to the use of microsomal triglyceride transfer protein (MTP) inhibitors. Based on the terms of the agreement, Aegerion can independently pursue product development opportunities involving MTP-based therapies as potential treatments to reduce LDL cholesterol. MTP inhibitors have been proven effective in reducing LDL levels in men and women and are being studied for potential use as monotherapies or in combination with statins or other therapies to reduce LDL cholesterol levels.

About Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company focused on the development and commercialization of promising pharmaceuticals to treat cardiovascular and metabolic disease. The company's initial focus is on hyperlipidemia. Its most advanced products are microsomal triglyceride transfer protein (MTP) inhibitors that have demonstrated significant LDL lowering activity in human trials and are currently in phase II testing.

Contact

Kate Childress, Vox Medica Health-care Public Relations Group
(t) 215-238-8500 ext 1107
(e) kchildress@voxmedica.com

###